Welcome to our dedicated page for Sol Gel Tech news (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol Gel Tech stock.
Sol-Gel Technologies Ltd. reports clinical, regulatory and commercial developments for a dermatology business focused on topical drug products for skin diseases. Company updates center on SGT-610, patidegib gel 2%, for the prevention of new basal cell carcinomas in Gorlin syndrome, and SGT-210, erlotinib ointment 5%, which has been evaluated in rare skin keratoderma indications including Darier disease.
News also covers TWYNEO for acne vulgaris and EPSOLAY for inflammatory lesions of rosacea, including product approvals and territorial licensing or commercialization arrangements. Financial releases discuss research and development spending, revenue tied to partnerships and approved products, cash resources, shareholder voting matters, and capital-structure actions such as the company's reverse share split.
Sol-Gel Technologies (NASDAQ: SLGL) announced positive pre-clinical data for its investigational drug, SGT-510, showing superiority over roflumilast cream in a psoriasis model. The human xenograft study, conducted at the Technion Institute, revealed a 60% recovery rate with SGT-510 compared to 30% with roflumilast. Sol-Gel also plans to develop tapinarof cream, aiming for affordability and innovation. Their study for SGT-210 indicated modest improvements in palmoplantar keratoderma. The company will discuss these results in a conference call today at 8 AM EDT.
Sol-Gel Technologies (NASDAQ: SLGL) has announced two exclusive 5-year license agreements with Galderma for the commercialization of its investigational products, EPSOLAY and TWYNEO, in the U.S. EPSOLAY targets inflammatory lesions of rosacea, while TWYNEO is aimed at treating acne vulgaris. The agreements could yield Sol-Gel up to $15 million in upfront and milestone payments, plus royalties ranging from mid-teen to high-teen percentages of net sales. These collaborations are expected to enhance Sol-Gel's financial position without dilution, while the products await FDA approval.
Sol-Gel Technologies, a clinical-stage dermatology firm, will present a company overview at two upcoming virtual investor conferences. The first is the Jefferies Healthcare Conference, scheduled for June 1, 2021, where CEO Dr. Alon Seri-Levy will speak at 8:30 am EDT. The second is the Raymond James Human Health Innovation Conference on June 22, 2021, at 10:00 am EDT. The company focuses on developing topical treatments for skin diseases, with NDA submissions for two products pending FDA review. Recordings of the presentations will be available on their website.
Sol-Gel Technologies (NASDAQ: SLGL) announced its Q1 2021 financial results, reporting revenue of $0.7 million and a loss of $4.1 million, down from a $7.1 million loss in Q1 2020. The company is in advanced negotiations for the commercialization of EPSOLAY® and TWYNEO® with PDUFA goal dates of April 26, 2021, and August 1, 2021, respectively. R&D expenses decreased to $2.5 million, primarily due to reduced clinical trial costs. Sol-Gel has $34.2 million in cash and equivalents expected to sustain operations into Q3 2022.
Sol-Gel Technologies (NASDAQ: SLGL) has provided an update on its EPSOLAY® (benzoyl peroxide) 5% topical cream, aimed at treating inflammatory lesions of rosacea. Initially scheduled for FDA action by April 26, 2021, the process has been delayed due to the COVID-19 pandemic impacting pre-approval inspections. The FDA confirmed that it could not proceed with the NDA until an inspection is conducted. Sol-Gel is actively following up with the FDA to schedule this inspection, as it remains crucial for the product's approval.
Sol-Gel Technologies (NASDAQ: SLGL) reported FY 2020 revenue of $8.8 million, driven largely by collaborations with Perrigo. The company achieved significant milestones, with FDA accepting NDAs for Epsolay and Twyneo, scheduled for PDUFA dates of April 26 and August 1, 2021, respectively. However, Sol-Gel incurred a net loss of $29.3 million, worsening from $24.6 million in 2019. Cash and securities totaled $50.2 million, expected to fund operations through Q3 2022. Operational plans include partnering for commercialization to enhance market capture.
Sol-Gel Technologies (NASDAQ: SLGL), a dermatology-focused clinical-stage company, announced its participation in upcoming virtual investor conferences. CEO Dr. Alon Seri-Levy will speak at the Raymond James Institutional Investors Conference on March 1, 2021, at 8:20 AM ET, while CFO Gilad Mamlok will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. A replay of the H.C. Wainwright presentation will be available on the company’s website for 30 days. The company continues to advance its pipeline of topical treatments for skin diseases.
Sol-Gel Technologies (NASDAQ: SLGL), a clinical-stage dermatology firm, announced its participation in two upcoming virtual investor conferences. Dr. Alon Seri-Levy, CEO, will present at the Solebury Trout 2021 Virtual Investor Conference from January 11-15, 2020, with on-demand access available. Additionally, CFO Gilad Mamlok will speak at the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2020, accessible to participants. Sol-Gel is focused on developing topical drugs for skin diseases, including treatments for acne and rosacea.
Sol-Gel Technologies (NASDAQ: SLGL) reported third-quarter 2020 revenues of $2.1 million, driven by generic product sales, with expectations of a revenue decrease due to increased competition. The FDA has accepted the New Drug Application (NDA) for Epsolay, targeting rosacea, with a PDUFA goal date of April 26, 2021. Additionally, an NDA for Twyneo has been submitted for acne treatment. The company reported a net loss of $8.6 million and has $57.3 million in cash and marketable securities, sufficient to fund operations through the third quarter of 2021.
Sol-Gel Technologies (NASDAQ: SLGL) announced its participation in two upcoming virtual investor conferences. The first is the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 8:30 AM ET, featuring CEO Dr. Alon Seri-Levy. The second is the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 5:00 PM GMT, with several executives, including CFO Gilad Mamlok. Webcasts of the presentations will be accessible on the company’s website.